Others have answered this perfectly well. but one more time.The...

Others have answered this perfectly well. but one more time.

The practitioner doesn't know if they have administered Rem or the placebo. They do not know if patient A is in the placebo group or Rem group. Hence, they cannot compare efficacy between patients or across groups (they don't know the groups). They could no doubt observe 'patient A' suddenly recover and have their interest peaked, but this is not enough to predict the outcome of overall trial. Especially as the trial is spread across 17+ hospitals and patients are receiving a variety of treatments and care levels.

We know Rem had an 83% survival rate in the small Mt Sinai EAP when SOC was not as good as it is now. We know there is a growing body of evidence to support that it will work. I am 50/50 if the trial is stopped early, but confident that the overall result will be positive. Either way, I'm holding for the outcome and for the phase III trials to come. oh and the FDA approval by no later than Sep 30.

An exciting time for MSB!